KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Research & Development (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Research & Development for 13 consecutive years, with $87.7 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 47.46% to $87.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $300.9 million through Dec 2025, up 43.04% year-over-year, with the annual reading at $300.9 million for FY2025, 43.04% up from the prior year.
  • Research & Development for Q4 2025 was $87.7 million at Xenon Pharmaceuticals, up from $77.1 million in the prior quarter.
  • The five-year high for Research & Development was $87.7 million in Q4 2025, with the low at $16.3 million in Q1 2021.
  • Average Research & Development over 5 years is $43.0 million, with a median of $42.0 million recorded in 2023.
  • The sharpest move saw Research & Development surged 104.11% in 2023, then rose 11.98% in 2024.
  • Over 5 years, Research & Development stood at $21.9 million in 2021, then soared by 59.14% to $34.8 million in 2022, then grew by 17.93% to $41.1 million in 2023, then soared by 44.79% to $59.5 million in 2024, then skyrocketed by 47.46% to $87.7 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $87.7 million, $77.1 million, and $75.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.